Authors

• Anna Turkina (ORCID: https://orcid.org/0000-0001-9947-2371)
• Jörge E. Cortes (ORCID: https://orcid.org/0000-0002-8636-1071)
• Giuseppe Saglio (ORCID: https://orcid.org/0000-0002-1046-3514)
• S. S. Kapoor (ORCID: https://orcid.org/0000-0003-4216-8488)
• Brian J. Nieman (ORCID: https://orcid.org/0000-0001-8914-3814)
• Timothy P. Hughes (ORCID: https://orcid.org/0000-0002-0910-3730)
• Jiřı́ Mayer (ORCID: https://orcid.org/0000-0003-0567-9887)
• Jan Geißler (ORCID: https://orcid.org/0000-0001-9058-5097)
• Ana Paula Cardoso (ORCID: https://orcid.org/0000-0001-5062-4098)
• Elza Lomaia
• Dong-Wook Kim (ORCID: https://orcid.org/0000-0002-3552-5988)
• Sara Quenet

Institutions

• Novartis (Switzerland) (CH)
• Masaryk University (CZ)
• Federal Almazov North-West Medical Research Centre (RU)
• Swiss Federal Archives (CH)
• National Medical Research Center for Hematology (RU)
• University Hospital Brno (CZ)
• The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
• Novartis (United States) (US)
• South Australian Health and Medical Research Institute (AU)
• National Cancer Center of Georgia (GE)
• University of Turin (IT)
• The University of Adelaide (AU)

Publication Details

Journal

Journal of Hematology & Oncology

Published

2024-12-18

DOI

https://doi.org/10.1186/s13045-024-01642-6

Citations

5

Primary Topic

Chronic Myeloid Leukemia Treatments

Type

article

Field-Weighted Citation Impact

2.27

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• Novartis Pharmaceuticals Corporation
• BeiGene
• Incyte
• Syndax Pharmaceuticals
• Ascentage Pharma
• Sun Pharma